Article successfully added.

CyFlow™ CD152 Low Endotoxin

CyFlow™ CD152 Low Endotoxin
Alternative Name: CTLA-4 , CTL Ag 4
Antibody: Yes
Antigen: CD152
Application: Flow cytometry, Immunocytochemistry, Immunohistochemistry (frozen sections), Immunoprecipitation
Clonality: monoclonal
Clone: BNI3
Field of Interest: Immunophenotyping
Format/Fluorochrome: Low Endotoxin
Isotype: IgG2a
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: AJ649823

For Research Use Only

$153.07 CAD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
Concentration Unit mg/mL Concentration 1 Quantity 0.1 mg Volume 0.1 mL... more
Close menu
CyFlow™ CD152 Low Endotoxin
Concentration Unitmg/mL
Concentration1
Quantity0.1 mg
Volume0.1 mL
ImmunogenHuman CD152-IgG heavy chain fusion protein
Background InformationCD152 (CTLA-4) is a homodimeric transmembrane protein similar to CD28 and binding the same ligands, i.e. CD80 (B7.1) and CD86 (B7.2), but with higher affinity. Unlike CD28 with important costimulating functions, CD152 acts as an important inhibitory receptor essential for modulation of the immune system. CD152 becomes transiently expressed on activated T cells and its malfunction can cause autoimmune diseases, such as insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, or thyroid-associated orbitopathy.
Storage BufferThe reagent is provided in azide-free phosphate buffered saline (PBS) solution, pH ≈7.4; 0.2 µm filter sterilized. Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Steiner K1, Waase I, Rau T, Dietrich M, Fleischer B, Bröker BM: Enhanced expression of CTLA‑4 (CD152) on CD4+ T cells in HIV infection. Clin Exp Immunol. 1999 Mar; 115(3):451‑7. < PMID: 10193417 > | Steiner K, Moosig F, Csernok E, Selleng K, Gross WL, Fleischer B, Bröker BM: Increased expression of CTLA‑4 (CD152) by T and B lymphocytes in Wegener's granulomatosis. Clin Exp Immunol. 2001 Oct; 126(1):143‑50. < PMID: 11678911 > | Chin LT, Chu C, Chen HM, Hsu SC, Weng BC, Chu CH: Site‑directed in vitro immunization leads to a complete human monoclonal IgG4 lambda that binds specifically to the CDR2 region of CTLA‑4 (CD152) without interfering the engagement of natural ligands. BMC Biotechnol. 2007 Aug 23; 7:51. < PMID: 17714596 > | Kraszula L, Eusebio M, Kupczyk M, Kuna P, Pietruczuk M: The use of multi‑color flow cytometry for identification of functional markers of nTregs in patients with severe asthma. Pneumonol Alergol Pol. 2012; 80(5):389‑401. < PMID: 22926900 > | Rissiek A, Baumann I, Cuapio A, Mautner A, Kolster M, Arck PC, Dodge‐Khatami A, Mittrücker HW, Koch‐Nolte F, Haag F, Tolosa E: The expression of CD39 on regulatory T cells is genetically driven and further upregulated at sites of inflammation. JAutoimmun. 2015 Apr; 58:12‐20. < PMID: 25640206 >

TDS & SDS
Close menu

Safety Data Sheet

Technical Data Sheet